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Abstract
Objective:  To  describe  the  epidemiological  proﬁle  and  the  survival  rate  of  patients  with  acute
myeloid leukemia  (AML)  in  a  state  reference  pediatric  hospital.
Method:  Clinical--epidemiological,  observational,  retrospective,  descriptive  study.  The  study
included new  cases  of  patients  with  AML,  diagnosed  between  2004  and  2012,  younger  than  15
years.
Results: Of  the  51  patients  studied,  84%  were  white;  45%  were  females  and  55%,  males.
Regarding  age,  8%  were  younger  than  1  year,  47%  were  aged  between  1  and  10  years,  and
45% were  older  than  10  years.  The  main  signs/symptoms  were  fever  (41.1%),  asthenia/lack  of
appetite (35.2%),  and  hemorrhagic  manifestations  (27.4%).  The  most  affected  extra-medullary
site was  the  central  nervous  system  (14%).  In  47%  of  patients,  the  white  blood  cell  (WBC)  count
was below  10,000/mm3 at  diagnosis.  The  minimal  residual  disease  (MRD)  was  less  than  0.1%,
on the  15th  day  of  treatment  in  16%  of  the  sample.  Medullary  relapse  occurred  in  14%  of  cases.
When comparing  the  bone  marrow  MRD  with  the  vital  status,  it  was  observed  that  71.42%  of
the patients  with  type  M3  AML  were  alive,  as  were  54.05%  of  those  with  non-M3  AML.  The  death
rate was  43%  and  the  main  proximate  cause  was  septic  shock  (63.6%).
Conclusions:  In  this  study,  the  majority  of  patients  were  male,  white,  and  older  than  1  year.
Most patients  with  WBC  count  <10,000/mm3 at  diagnosis  lived.  Overall  survival  was  higher  in
patients  with  MRD  <0.1%.  The  prognosis  was  better  in  patients  with  AML-M3.
© 2016  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved. Please cite this article as: de Lima MC, da Silva DB, Freund AP, Dacoregio JS, Costa TE, Costa I, et al. Acute Myeloid Leukemia: analysis
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Leucemia  Mielóide  Aguda:  análise  do  perﬁl  epidemiológico  e  taxa  de  sobrevida
Resumo
Objetivo:  Descrever  o  perﬁl  epidemiológico  e  a  taxa  de  sobrevida  dos  pacientes  com  Leucemia
Mielóide  Aguda  (LMA),  em  um  hospital  pediátrico  de  referência  estadual.
Método:  Estudo  clínico-epidemiológico,  observacional,  retrospectivo  e  descritivo.  Foram  incluí-
dos casos  novos  de  pacientes  com  LMA,  diagnosticados  entre  os  anos  de  2004  e  2012,  com  idade
<15 anos.
Resultados:  Entre  os  51  pacientes  estudados,  84%  eram  da  rac¸a  branca,  45%  do  sexo  femi-
nino e  55%  do  masculino.  Quanto  a  faixa  etária,  8%  tinham  idade  <1  ano,  47%  entre  1  e  10
anos e,  45%  >10  anos.  Os  principais  sinais/sintomas  ao  diagnóstico  foram  febre  (41,1%),  aste-
nia/inapetência  (35,2%)  e  manifestac¸ões  hemorrágicas  (27,4%).  O  Sistema  Nervoso  Central  foi  o
local extra-medular  mais  acometido  (14%).  Em  47%  dos  pacientes  a  leucometria  ao  diagnóstico
foi <10.000/mm3.  A  doenc¸a  residual  mínima  (DRM)  no  15◦ dia  de  tratamento  foi  <0,1%  em  16%
da casuística.  Recidiva  medular  ocorreu  em  14%  dos  casos.  Ao  se  comparar  a  DRM  da  medula
óssea com  o  status  vital,  observou-se  que  estavam  vivos  71,42%  dos  pacientes  com  LMA  tipo  M3
e 54,05%  daqueles  com  LMA  não-M3.  A  taxa  de  óbito  foi  de  43%  e  a  principal  causa  imediata  foi
o choque  séptico  (63,6%).
Conclusões:  Neste  estudo,  a  maioria  dos  pacientes  é  do  sexo  masculino,  rac¸a  branca,  maiores
que 1  ano  de  idade.  A  maioria  dos  pacientes  com  leucometria  <10.000/mm3 ao  diagnóstico  está
viva. A  sobrevida  global  é  maior  nos  pacientes  com  DRM  <0,1%.  O  prognóstico  é  melhor  nos
pacientes  com  LMA-M3.
©  2016  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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Introduction
cute  myeloid  leukemia  (AML)  is  a  clonal  disease  of
ematopoietic  tissue  characterized  by  abnormal  prolifera-
ion  of  progenitor  cells  of  myeloid  lineage,  resulting  in  the
nsufﬁcient  generation  of  normal  mature  blood  cells.1
It  represents  approximately  15--20%  of  acute  leukemia
ases  in  childhood,1 and  accounts  for  about  30%  of  deaths
n  this  age  range.2 In  Brazil,  its  estimated  incidence  is  400
ases  per  year.3
Hemorrhagic  manifestations,  fever,  and  pallor  are  fre-
uent  symptoms  of  the  disease  at  diagnosis.  The  main  causes
f  death  are  infections,  bleeding  episodes,  leukostasis,  and
umor  lysis  syndrome.4
The  main  factors  affecting  the  mortality  rate  of  these
atients  are  those  resulting  from  therapy  intensiﬁcation  and
isease  relapse.5,6
AML  prognosis  improvement  has  been  made  possible  by
isease  stratiﬁcation  into  risk  groups  based  on  cytogene-
ics,  the  evaluation  of  early  response  to  treatment,  and  the
dentiﬁcation  of  chemotherapy-induction  failure.  Currently,
he  likelihood  of  AML  cure  in  developed  countries  is  around
0%.7,8
Considering  that  in  recent  decades  there  has  been
rogress  in  the  introduction  of  new  chemotherapy  treat-
ent  protocols  for  AML  and  that  the  information  in  the
ediatric  population  and  its  clinical  outcomes  are  still
carce,  this  study  aimed  to  analyze  the  eight-year  expe-
ience  in  a  pediatric  oncology  service,  in  the  South  of
razil.
G
l
oethods
his  was  a  clinical--epidemiological,  observational,  ret-
ospective,  descriptive  study  approved  by  the  Ethics
ommittee  on  Human  Research  of  Hospital  Infantil  Joana
e  Gusmão  (HIJG).
The  study  included  all  new  cases  of  AML  patients  younger
han  15  years  treated  in  HIJG  between  January  2004  and
ugust  2012.
Exclusion  criteria  were  loss  to  follow-up;  patient  transfer
o  another  service;  insufﬁcient  data  at  the  hospital  cancer
egistry  and  medical  records  and  statistics  department  of
IJG.
The  diagnosis  of  AML  was  based  on  morphology,  cyto-
hemistry,  and  immunophenotyping  by  ﬂow  cytometry  of
one  marrow  aspirate  and/or  peripheral  blood,  performed
ith  EuroFlow  8-color  antibody  panels  (EuroFlow-ESLHO,
otterdam,  NL).  The  minimal  residual  disease  (MRD)  was
nalyzed  by  ﬂow  cytometry  in  the  bone  marrow  after  15
ays  of  induction  treatment.  The  treatment  protocols  used
ere  from  the  International  Berlin-Frankfurt-Münster  (BFM)
tudy  Group  AML-83  (n  = 6),  AML-98  (n  =  22),  and  AML-2004
n  = 23).
The  analyzed  variables  were  age  at  diagnosis  (age  range
tratiﬁed  as  <1  year,  1  year  to  10  years,  and  >10  years);
ender;  ethnicity/skin  color,  as  established  by  the  Brazilian
nstitute  of  Geography  and  Statistics  (Instituto  Brasileiro  de
eograﬁa  e  Estatística  --  IBGE)  as  white,  black,  brown,  yel-
ow,  and  indigenous;  origin,  according  to  the  mesoregions
f  the  state  of  Santa  Catarina  established  by  IBGE  (city  of
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Table  1  Signs  and  symptoms  at  diagnosis  in  number  (n)
and percentage  (%)  of  patients  with  acute  myeloid  leukemia
treated  in  Hospital  Infantil  Joana  de  Gusmão  (HIJG),  from
2004  to  2012.
Signs/symptoms  n  %
Pallor 13  25.40%
Hemorrhagic  manifestations 14  27.40%
Fever 21  41.10%
Asthenia/lack  of  appetite  18  35.20%
Increase  in  soft  tissue  volume  4  7.80%
Bone pain  11  21.50%
Abdominal  pain  2  3.90%
Adenomegaly  2  3.90%
Gingival  hypertrophy  3  5.80%
Respiratory  symptoms  4  7.80%
Table  2  Hematological  alterations  and  French--American--
British  (FAB)  classiﬁcation  at  diagnosis  of  patients  with  acute
myeloid  leukemia  treated  at  Hospital  Infantil  Joana  de
Gusmão (HIJG),  from  2004  to  2012.
Hematological  alterations  n  %
White  blood  cell  count
<10,000  24  47%
10,000--50,000  17  33%
>50,000--100,000  4  8%
>100,000  3  6%
Not mentioned  3  6%
No. of  platelets
<20,000  11  22%
20,000--100,000  29  57%
>100,000  8  16%
Not mentioned  3  6%
Neutropenia
Yes 21  41%
No 27  53%
Not mentioned  3  6%
FAB n  %
M0  6  12%
M1 1  2%
M2 14  27%
M3 14  27%
M4 8  16%
M5 4  8%
M6 1  2%
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Florianópolis,  Northern  Santa  Catarina,  Western  Santa  Cata-
rina,  Mountain  Region,  Southern  Santa  Catarina,  Valley  of
Itajaí)  and  others  (from  other  states);  predominant  signs  and
symptoms  at  diagnosis  (fever,  bone  pain,  abdominal  pain,
enlarged  lymph  nodes,  hemorrhagic  manifestations,  gingi-
val  hypertrophy,  pallor,  asthenia/lack  of  appetite,  swelling
of  soft  tissue,  and  respiratory  symptoms);  laboratory  ﬁnd-
ings  at  diagnosis  (white  blood  cell  count,  neutropenia,  and
platelet  count);  extramedullary  involvement  at  diagnosis
(CNS  or  other  sites);  AML  classiﬁcation  according  to  the
French--American--British  group  (FAB)1;  presence  and  type
of  laboratory  genetic  alterations;  presence  or  absence  of
clinical  and  laboratory  remission  after  the  ﬁrst  chemother-
apy  induction,  according  to  the  MRD  value  on  the  15th  day
of  induction,  obtained  by  ﬂow  cytometry;  vital  status  (alive
or  deceased);  death  (in  remission  or  not  from  neoplastic  dis-
ease),  immediate  cause  of  death;  presence  and  location  of
disease  recurrence  (bone  marrow,  extramedullary,  or  com-
bined);  and  bone  marrow  transplantation.
The  statistical  procedures  used  in  the  study  were  descrip-
tive  measures,  frequency  tables,  and  Pearson’s  chi-squared
test,  with  95%  of  signiﬁcance  (p  <  0.05)  to  analyze,  as  an
exploratory  characteristic,  the  association  between  two
variables.  Associations  were  veriﬁed  between  the  variables
vital  status  and  white  blood  cell  count,  vital  status  and  type
M3-AML  MRD,  and  vital  status  and  non-M-AML  MRD.
Results
Of  the  51  patients,  55%  (n  =  28)  were  males  and  45%
(n  =  23)  females,  at  a  ratio  of  1.2:1.  Whites  predominated,
accounting  for  84%  of  patients.  Brown  and  black  patients
represented  16%  of  the  sample.
Mean  age  at  diagnosis  was  7.3  years  (SD  ±  4.8  years)  with
a  median  of  9  years.  The  youngest  age  at  diagnosis  was  19
days  and  the  oldest,  14  years.  Regarding  the  age  range,  8%
of  the  sample  were  aged  <1  year,  47%  were  between  1  and
10  years,  and  45%  were  >10  years.
As  for  the  origin,  according  to  the  mesoregions  of  Santa
Catarina  by  IBGE,  29%  were  from  the  city  of  Florianópolis
(n  =  15),  24%  were  from  the  Western  Region  (n  =  12),  20%
from  the  Mountain  Region  (n  =  10),  10%  from  the  Northern
Region  (n  =  5),  8%  from  the  Southern  Region  (n  =  4),  8%  from
the  Itajai  Valley  (n  =  4),  and  2%  (n  =  1)  were  from  another
state,  Paraná.
The  main  signs  and  symptoms  at  diagnosis  are  described
in  Table  1.
At  diagnosis,  24%  of  patients  had  extramedullary  disease
(n  =  12),  and  the  most  often  affected  site  was  the  central
nervous  system  (CNS)  in  14%  (n  =  7).  The  other  10%  had
skin  involvement  (n  =  2),  bone  involvement,  and  soft  tissue
edema  (n  =  3).
Laboratory  data  at  AML  diagnosis  (leukocytes,  platelets,
and  neutropenia)  and  morphological  FAB  classiﬁcation  are
described  in  Table  2.
When  correlating  WBC  count  at  diagnosis  with  vital  sta-
tus  (p  =  0.014),  it  was  observed  that  79.2%  of  patients  with
WBC  count  <10,000  lived,  whereas  29.4%  of  those  with  WBC
counts  between  10,000  and  50,000  lived.  The  three  patients
(6%)  that  had  WBC  count  >100,000  died.
The  study  of  genetic  disorders  was  documented  in  51%
of  patients  (n  =  26),  showing  alterations  in  46.15%  of  cases
o
o
(M7 3  6%
n  =  12).  The  most  frequent  alteration  was  t(15;17),  found
n  six  patients  (23%).  One  of  these  patients  had  an  associa-
ion  of  t(15;17)  with  FLT3-ITD  mutation.  The  other  genetic
isorders  found  were  polyploidy,  t(8;21),  presence  of  MLL
earrangement,  t(3;5)  deletion  of  chromosome  18,  trisomy
f  chromosome  21,  trisomy  of  chromosome  8,  and  tetrasomy
f  chromosome  8.
MRD  analysis  in  45%  of  patients  (n  =  23)  was  <0.1%;  in  16%
n  =  8)  it  was  between  0.1%  and  1.0%;  in  25%  (n  =  13)  it  was
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Table  3  Minimal  residual  disease  (MRD)  in  bone  marrow  on  the  15th  day  of  treatment  of  acute  promyelocytic  leukemia  (M3-AML)
and vital  status  of  patients  treated  at  Hospital  Infantil  Joana  de  Gusmão  (HIJG),  from  2004  to  2012  (p  =  0.025).
MRD  Vital  status
Alive  Dead  Total
n  %  n  %  n  %
<0.1%  6  42.85%  0  0  6  42.85%
0.1--1.0% 1  7.14%  0  0  1  7.14%
>1.0% 3  21.44%  1  7.14%  4  28.58%
Not mentioned  0  0  3  21.44%  3  21.44%
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1.0%;  14%  (n  =  7)  of  the  cases  lacked  the  test  result  in  the
edical  record.
The comparison  between  the  bone  marrow  MRD,  on  the
5th  day  of  treatment  and  the  vital  status  of  patients
ith  acute  promyelocytic  leukemia  (M3-AML)  and  acute
on-promyelocytic  leukemia  (non-M-AML)  is  described  in
ables  3  and  4.
Overall  survival  was  57%  in  this  study.  By  correlating  vital
tatus  with  M3-AML  and  non-M-AML,  it  was  observed  that
1.42%  and  54.05%  of  the  patients  were  alive,  respectively,
t  the  end  of  the  study.
Of  the  patients  who  died  (n  −  22),  64%  (n  =  14)  were
ot  in  complete  clinical  remission  of  leukemia  at  the  end
f  chemotherapy  induction.  The  main  immediate  cause  of
eath  was  septic  shock  in  63.6%  of  patients  (n  =  14).  Of  the
eaths,  three  occurred  within  the  ﬁrst  15  days  of  treat-
ent,  one  from  intracranial  hemorrhage  (M3-AML)  and  the
ther  two,  in  addition  to  sepsis,  had  pulmonary  leukostasis
nd  intracranial  hemorrhage  with  spinal  ﬂuid  inﬁltrate  at
iagnosis,  respectively.
Regarding  the  deaths  that  occurred  after  the  16th  day
f  induction  treatment  (n  =  19),  12  occurred  due  to  septic
hock.  Of  these,  six  occurred  after  chemotherapy  re-
nduction  for  recurrence.
Of  patients  with  WBC  count  >100,000,  one  patient  had
3-AML,  whose  immediate  cause  of  death  was  septic  shock,
nother  had  M0-AML  with  pulmonary  leukostasis  associated
ith  septic  shock,  and  the  other  had  M5-AML  with  acute
enal  failure.
Regarding  the  patients  (n  =  6)  that  had  t(15;17)  muta-
ions,  two  died.  The  patient  that  had  t(15;17)  and  FLT3-ITD
utations  was  alive  and  in  remission  until  the  date  of  com-
letion  of  this  study.
Among  the  assessed  patients,  39%  (n  =  20)  were  submitted
o  radiotherapy  and  16%  (n  =  8)  to  bone  marrow  transplan-
ation  (BMT).  Of  the  patients  who  underwent  BMT,  two
ied  and  the  others  are  alive  and  in  complete  remission  of
eukemia.
In  14%  of  cases  (n  =  7)  there  was  disease  recurrence  in  the
one  marrow  and,  of  these,  six  patients  died.
iscussionn  this  study,  most  patients  were  male  and  older  than  1  year.
ost  of  those  that  had  WBC  count  <10,000/mm3 at  diagnosis
re  alive.
l
w
t
M4  28.58%  14  100%
Overall  survival  is  higher  in  patients  with  MRD  <0.1%  and
he  prognosis  is  better  in  patients  with  M3-AML.
In  other  studies,9,10 male  gender  also  showed  a  slight
redominance  to  females  (1.2:1).
As  in  the  study  by  Kavcic,10 it  was  observed  that  AML
redominated  in  whites.  In  Santa  Catarina,  as  a  result  of
he  white  descent  of  the  majority  of  the  population,  white
thnicity  was  predominant,  making  it  impossible  to  establish
omparisons  between  the  ethnic  groups.
Corroborating  other  studies,10--12 this  study  showed  a
igher  prevalence  of  AML  in  the  age  range  >1  year  old.
This  study,  as  in  the  literature,  also  demonstrated  that
he  signs  and  symptoms  of  AML  result  from  bone  marrow
nﬁltration,  with  hemorrhagic  manifestations,  fever,  asthe-
ia,  pallor,  and  bone  pain.2
In  previously  published  studies,  the  percentage  of  CNS
nvolvement  at  diagnosis  ranged  from  5%  to  15%.2,13 In  this
tudy,  14%  of  patients  had  CNS  involvement  at  diagnosis,
imilarly  to  what  was  described  by  Rubnitz  et  al.13
Studies  have  shown  that  the  percentage  of  patients  with
BC  counts  >100,000/mm3 is  between  12%  and  15%.6,9,14 In
his  series,  only  6%  of  cases  had  this  elevated  WBC  count  at
iagnosis.  This  difference  can  be  explained  by  the  lack  of
ata  available  in  the  medical  records  of  some  patients,  the
ize  of  this  sample,  or  the  earlier  disease  diagnosis.
WBC  count  is  the  most  important  risk  factor  for  treat-
ent  failure,  due  to  the  possibility  of  causing  bleeding
omplications  or  respiratory  failure  due  to  leukostasis.9,15
he  present  study  showed  that  80%  of  patients  had  WBC
ount  <50,000/mm3 at  diagnosis,  similar  to  the  study  by
mamura  et  al.14
The  probability  of  event-free  survival  (EFS)  in  ﬁve  years
as  only  23%  in  patients  with  WBC  count  >100,000/mm3
ccording  to  the  analysis  of  the  BFM-83  and  BFM-87  treat-
ent  protocols.9 This  study  showed  that  79.2%  of  the
atients  (p  =  0.014)  with  WBC  count  <10,000/mm3 at  diag-
osis  lived,  whereas  among  those  with  WBC  counts  between
0,000  and  50,000/mm3, only  29.4%  lived.  Only  three
atients  in  this  study  had  a WBC  count  >100,000/mm3
t  diagnosis,  thus  making  the  statistical  analysis
mpossible.
The  FAB  morphological  classiﬁcation  for  AML  can  deﬁne
reatment  and  risk  group  stratiﬁcation.3 In  previously  pub-
ished  studies9,14,16 the  most  frequently  identiﬁed  subtype
as  M2,  ranging  from  33.6%  to  37%.  In  the  present  study,
he  most  prevalent  morphological  types  were  M2  (27%)  and
3  (27%),  similar  to  the  ﬁndings  of  Xiao-Jun  Xu  et  al.6
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Table  4  Minimal  residual  disease  (MRD)  in  bone  marrow  on  the  15th  day  of  treatment  of  non-acute  promyelocytic  leukemia
(non-M3-AML)  and  vital  status  of  patients  treated  at  Hospital  Infantil  Joana  de  Gusmão  (HIJG),  from  2004  to  2012  (p  =  0.019).
MRD  Vital  status
Alive  Dead  Total
n  %  n  %  n  %
<0.1%  13  35.14%  4  10.81%  17  45.95%
0.1--1.0% 5  13.51%  3  8.11%  8  21.62%
>1.0% 2  5.40%  6  16.22%  8  21.62%
Not mentioned  0  0  4  10.81%  4  10.81%
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After  the  advent  of  all-trans-retinoic  acid  (TRA),  M3-AML
became  the  FAB  subtype  with  the  best  prognosis,  by  inducing
the  differentiation  of  leukemic  precursors  into  mature  cells,
controlled  by  this  drug.1,17 The  present  study  also  found  good
therapeutic  response  to  this  medication,  considering  that
71.42%  of  patients  with  M3-AML  and  54.05%  of  those  with
non-M3-AML  were  alive  at  the  end  of  this  study.
AML  is  a  heterogeneous  disease  from  the  molecular  point
of  view,  including  somatic  and  epigenetic  alterations  that
contribute  to  myeloid  leukemogenesis.  These  cytogenetic
abnormalities,  somatic  mutations,  and  the  induction  ther-
apy  response  are  important  information  for  risk  stratiﬁcation
and  adequate  therapy  allocation.18
Chromosomal  abnormalities  in  AML  include  aberrations
described  as  gain  or  loss  of  whole  chromosomes  structural
abnormalities  or  balanced  translocations.19 The  literature
reports  that  the  translocation  t(8;21)  is  the  most  preva-
lent,  varying  between  12%  and  23%,12--14 whereas  t(15;17)
is  observed  in  3.4--10%  of  cases.12,13
According  to  the  present  results,  46%  of  the  assessed
patients  have  some  cytogenetic  alteration,  and  transloca-
tion  t(15;17)  was  most  prevalent  (23%),  which  is  justiﬁed  by
the  number  of  cases  of  M3-AML  in  this  study.  As  this  alter-
ation  has  a  favorable  prognosis,  it  conﬁrms  the  ﬁndings  of
increased  survival  in  patients  with  M3-AML.  It  is  notewor-
thy  that  the  cytogenetic  analysis  of  patients  in  this  study
was  documented  in  only  51%  of  cases,  which  might  have
underestimated  the  results.
A  recent  study15 stated  that  survival  is  poor  in  patients
with  translocation  t(15;17)  and  FLT3-ITD  mutation  associa-
tion,  thus  representing  an  independent  prognostic  predictor,
with  a  progression-free  survival  rate  of  16%.  In  the  present
series,  only  one  patient  with  M3-AML  had  the  translocation
t(15;17)  and  FLT3-ITD  association,  and  was  alive  and  without
signs  of  relapse  at  the  end  of  the  study.
In  the  BFM  study,  bone  marrow  MRD  measured  after
the  ﬁrst  treatment  course  was  the  best  event-free  survival
predictor  when  compared  to  the  risk  classiﬁcation  scheme
by  FAB  subtype,  cytogenetics,  and  the  presence  of  blasts
in  peripheral  blood  morphology  on  the  15th  day  of  anti-
neoplastic  treatment.15 The  presence  of  high  MRD  after  the
ﬁrst  course  of  induction  was  signiﬁcantly  associated  with  an
adverse  outcome.  The  recurrence  rate  was  particularly  high
(49%)  in  patients  with  MRD  >1%,  while  in  patients  with  lower
MRD  (0.1--1%),  the  rate  was  only  17%.15
The  study  by  Al-Mawali  et  al.20 also  demonstrated
that  MRD  >0.15%  was  an  independent  predictor  of  poor
t
i
r
w7  45.95%  37  100%
rognosis  after  chemotherapy  induction.  Other  studies  have
lso  demonstrated  a  correlation  between  MRD  <0.1%  and
mproved  event-free  survival,  such  as  the  study  by  Rubnitz
t  al.21 and  Inaba  et  al.22,23
Although  MRD  is  a  strong  prognostic  factor,  approximately
5%  of  patients  with  low  MRD  will  have  disease  recurrence.
he  study  by  Karol  et  al.24 identiﬁed,  among  the  risk  factors
or  recurrence,  certain  11q23  abnormalities  such  as  t(6;11)
nd  t(10;11),  megakaryocytic  leukemia  without  t(1:22),  and
ge  ≥10  years.24
In  this  study,  when  comparing  the  MRD  <0.1%  on  the  15th
ay  of  treatment  with  vital  status,  it  was  observed  that  100%
f  patients  with  M3-AML  and  76.5%  of  patients  with  non-M3-
ML  were  alive,  respectively.  When  MRD  was  >1.0%,  it  was
bserved  that  75%  of  M3-AML  patients  and  25%  of  non-M3-
ML  patients  were  alive.  There  was  a statistical  signiﬁcance
etween  bone  marrow  MRD  and  vital  status  (p  =  0.022),  as
ell  as  between  M3-AML  and  vital  status  (p  =  0.025)  and  non-
3-AML  and  vital  status  (p  =  0.019).  These  data  corroborate
he  prognostic  importance  of  MRD  quantiﬁcation.
Regarding  recurrence,  the  bone  marrow  is  the  most  fre-
uent  site  of  AML  relapse.15 In  this  series,  all  recurrences
ccurred  at  this  site.
Recent  antineoplastic  therapies,  such  as  new  chemother-
peutic  agents,  monoclonal  antibodies,  and  immunomodu-
ators,  are  challenges  in  the  assessment  of  the  impact  on  the
hild’s  immune  function  and  of  infectious  complications.19
The  literature  reports  that  the  leading  cause  of  death  in
hese  patients  is  infection,  and  that  it  is  mainly  related  to
hemotherapy  intensiﬁcation.5,6,9
A  study  by  Silva  et  al.,25 analyzing  mortality  trends  in
razil  in  children  with  leukemia  in  the  1980--2010  period,
eports  that  the  deaths  associated  to  the  treatment  of
cute  myeloid  leukemia  in  less  developed  countries  can
each  up  to  33%,  as  the  intensive  chemotherapy  regimen
redisposes  to  severe  neutropenia  and  exposes  patients  to
nfections.
Pediatric  patients  treated  for  AML  are  at  high  risk  for
nfectious  complications,  predominantly  bacterial  and  fun-
al.  Some  institutions  have  implemented  prophylaxis  with
ntibiotic  and  anti-fungal  agents,  aimed  at  reducing  these
nfections.  However,  the  systematic  evaluation  of  antibiotic
rophylaxis  studies  indicates  that  there  is  insufﬁcient  data
o  deﬁne  guidelines  for  their  use.  Therefore,  additional  stud-
es  are  needed  to  accurately  identify  the  best  antibiotic
egimen,  as  well  as  for  which  population  of  children  they
ould  be  indicated.26,27
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The  present  study  also  showed  that  septic  shock  (63.6%)
as  the  most  prevalent  cause  of  death.  Of  the  19  patients
hat  died  after  the  15th  day  of  the  induction  therapy,  six
ad  relapsed.  The  deaths  that  occurred  in  this  period  were
robably  due  to  infections  after  aplasia  induction.
In  recent  decades,  in  spite  of  the  improved  AML  prog-
osis,  approximately  one-third  of  patients  had  recurrence.
his  population  has  a  poor  prognosis,  with  long-term  sur-
ival  probability  of  approximately  35%,  despite  the  use  of
ntensive  chemotherapy  and  allogeneic  bone  marrow  trans-
lantation.  The  toxicity  and  mortality  resulting  from  this
reatment  are  also  signiﬁcant.28
Currently,  studies  with  targeted  therapies  are  being
eveloped,  focusing  primarily  on  the  functional  pathways
f  leukemic  cells,  such  as  cell  surface  receptors,  speciﬁc
ntracellular  kinases,  proteins  that  regulate  cell  death  and
ene  expression  modulators,  aiming  to  improve  AML  patient
urvival.29
AML  treatment  should  be  based  on  a  clinical  structure
apable  of  supporting  the  therapeutic  aggressiveness,  in
ddition  to  a  laboratory  structure  capable  of  discriminat-
ng  the  risk  groups  and  contributing  to  the  identiﬁcation  of
elevant  prognostic  factors,  as  well  as  providing  supportive
easures  for  the  care  of  these  patients.
In  this  series,  selection  bias  was  considered  due  to  the
nclusion  of  all  cases  diagnosed  at  the  service.  These  results
ay  have  been  inﬂuenced  by  characteristics  of  the  assessed
opulation;  the  different  treatment  protocols  used  (BFM);
he  available  medical  and  hospital  resources  in  this  service;
nd  the  sample  size.  However,  the  results  observed  in
his  study  show  the  need  to  perform  national,  multicenter,
nalytical  studies,  aiming  at  conﬁrmation  of  the  observed
ssociations  and  thus,  establishing  prognostic  factors  for
ML.
In  this  study,  the  comparison  of  bone  marrow  MRD  on  the
5th  day  of  induction  treatment  with  vital  status  showed
hat  71.42%  of  patients  with  type  M3  AML  and  54.05%  of
hose  with  non-M3-AML  were  alive.  The  death  rate  was  43%
nd  the  main  immediate  cause  was  septic  shock  (63.6%).
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